Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

  • Awaiting development
  • GID-TA11440
  • Expected publication date: TBC

NIHRIO BN: 33898-Durvalumab-FLOT-for-Gastro-Oesophageal-Junction-Cancer-V1.0-SEP2023-NON-CONF.pdf (nihr.ac.uk)